Search - tctmd.com

Displaying 201 - 220 of 259

Sort: Relevancy | Date

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

Caitlin E. Cox

January 18, 2018

News Daily News

Cardiac Rehab Rates Still Low in Medicare and VA Populations

L.A. McKeown

January 09, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Shelley Wood

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

News Daily News

CTA Reduces MI Compared With Functional Stress Testing, but at a Cost

Michael O'Riordan

October 05, 2017

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Readmissions After Acute MI Not Only Confined to the Elderly

Yael L. Maxwell

August 09, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

Elevated Cardiovascular Risk May Linger for Several Years After a Severe Infection

Todd Neale

August 02, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

Advertisement

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

Cardiac Rehab Rates Still Low in Medicare and VA Populations

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Blood in Urine Carries Consequences for Patients on Antithrombotics

CTA Reduces MI Compared With Functional Stress Testing, but at a Cost

Generic ARBs Linked to Increased Adverse Events

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Readmissions After Acute MI Not Only Confined to the Elderly

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Elevated Cardiovascular Risk May Linger for Several Years After a Severe Infection

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content